Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...
Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results